{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-003036","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.674273+00:00","generated_at":"2026-05-24T14:55:00.400723+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Protalix FY 2024: Record product revenue $53M (+31%), net income $2.9M; debt-free","bullets":["Revenue from goods $53.0M (+31% YoY), driven by Chiesi sales (+$11.8M); total revenue $53.4M vs $65.5M in 2023.","Net income $2.9M ($0.04/sh diluted) vs $8.3M ($0.12/sh basic) in 2023; lower due to absence of $20M milestone.","Cash $34.8M; convertible notes fully repaid Sep 2024; no warrants remaining after March 2025 expiration.","PRX-115 (gout) phase I completed; phase II expected H2 2025; EMA validated less frequent dosing for pegunigalsidase alfa."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-003036","json":"https://secwatch.observer/filing/0001558370-25-003036.json","markdown":"https://secwatch.observer/filing/0001558370-25-003036.md","text":"https://secwatch.observer/filing/0001558370-25-003036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025003036/0001558370-25-003036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025003036/plx-20250317x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T14:55:00.400723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}